Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $51.00.
A number of research analysts have weighed in on the stock. Needham & Company LLC cut their price objective on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Piper Sandler restated a “neutral” rating and set a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Wall Street Zen downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th.
Read Our Latest Stock Report on COLL
Collegium Pharmaceutical Price Performance
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The business had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The business’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.68 EPS. As a group, sell-side analysts expect that Collegium Pharmaceutical will post 6.51 EPS for the current year.
Institutional Investors Weigh In On Collegium Pharmaceutical
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Collegium Pharmaceutical in the second quarter valued at $196,972,000. Rubric Capital Management LP lifted its holdings in shares of Collegium Pharmaceutical by 5.3% in the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after purchasing an additional 157,743 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Collegium Pharmaceutical by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after purchasing an additional 29,876 shares during the period. Jupiter Topco LLC acquired a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $77,743,000. Finally, Janus Henderson Group PLC grew its stake in Collegium Pharmaceutical by 26.0% during the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock worth $60,358,000 after buying an additional 377,073 shares during the last quarter.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.
The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.
Featured Stories
- Five stocks we like better than Collegium Pharmaceutical
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
